Embolx said today that it landed a $2 million grant from the National Cancer Institute to fund development of its next-generation Sniper balloon occlusion microcatheter.
The Sunnyvale, Calif.-based medical device company has developed a drug-delivery system that administers therapies into targeted areas of the body by controlling pressure. Embolx’s Sniper balloon is designed to treat cancerous tumors, benign prostatic hyperplasia and uterine fibroids, according to the company.
Get the full story at our sister site, Drug Delivery Business News.
The post Embolx wins $2m NIH grant for pressure-directed embolization therapy appeared first on MassDevice.